⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.

Official Title: An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Study ID: NCT01022996

Interventions

Everolimus (RAD001)

Study Description

Brief Summary: This study will assess RAD001 in patients with refractory or relapsed Hodgkin Lymphoma that has progressed after high-dose chemotherapy and Autologous Stem cell transplant and/or after gemcitabine- or vinorelbine- or vinblastine-based treatment.

Detailed Description:

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

University of California at Los Angeles UCLS School of Medicine, Los Angeles, California, United States

Rocky Mountain Cancer Centers RMCC - Aurora, Greenwood Village, Colorado, United States

MD Anderson Cancer Center - Orlando, Orlando, Florida, United States

Emory University School of Medicine/Winship Cancer Institute Emory University Med School, Atlanta, Georgia, United States

Lurie Children's Hospital of Chicago Robert H. Lurie Comp Cancer, Chicago, Illinois, United States

Indiana University Simon Cancer Center, Indianapolis, Indiana, United States

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Karmanos Cancer Institute Karmanos-1, Detroit, Michigan, United States

Mayo Clinic - Rochester Mayo Lymphoma Group, Rochester, Minnesota, United States

Washington University School Of Medicine-Siteman Cancer Ctr StudyCoordinator:CLBH589B2201, St. Louis, Missouri, United States

New York Presbyterian Hospital Weill Cornell Med Ctr, New York, New York, United States

Duke University Medical Center Duke University Medical Ctr, Durham, North Carolina, United States

University of Tennessee Cancer Institute Univ Tennessee Cancer, Memphis, Tennessee, United States

University of Texas/MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(3), Houston, Texas, United States

University of Wisconsin Comprehensive Cancer Center Clinical Science Center - H4, Madison, Wisconsin, United States

Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Contact Details

Name: Novartis Pharmaceuticals

Affiliation: Novartis Pharmaceuticals

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: